Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01778049
First received: January 24, 2013
Last updated: September 19, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: March 2015
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)